Literature DB >> 25301099

No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer.

Dominik Riss1, Johannes Pammer, Matthaeus C Grasl, Alexandra Kaider, Sven Schneider, Boban M Erovic.   

Abstract

PURPOSE: To investigate the role of desmocollin 3 expression in radiation sensitivity and survival in squamous cell carcinoma of the head and neck.
METHODS: Tissue samples of 40 patients undergoing primary radiotherapy were stained for desmocollin 3, a transmembrane desmosomal protein. The protein expression was determined by immunohistochemistry. A retrospective chart review was performed to assess overall survival, radiation sensitivity, and disease-free interval.
RESULTS: 18 of 40 patients showed desmocollin 3 immunoreactivity. 78 % (14/18) showed radiation sensitivity in the desmocollin 3 positive group, whereas 59 % (13/22) underwent remission in the desmocollin 3 negative group (p = 0.2). The median overall and disease-free survival time was 21 and 26 months, respectively. Univariate and multivariable Cox regression models revealed no statistically significant hazard ratios.
CONCLUSION: In this cohort of squamous cell carcinoma of the head and neck, we found no evidence for a predictive potential of desmocollin 3.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301099     DOI: 10.1007/s00508-014-0618-1

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  18 in total

Review 1.  Exploring biomarkers in head and neck cancer.

Authors:  Corey J Langer
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

Review 2.  The desmosome.

Authors:  Emmanuella Delva; Dana K Tucker; Andrew P Kowalczyk
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-08       Impact factor: 10.005

3.  A note on quantifying follow-up in studies of failure time.

Authors:  M Schemper; T L Smith
Journal:  Control Clin Trials       Date:  1996-08

4.  Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma.

Authors:  Zaur Hamidov; Annelore Altendorf-Hofmann; Yuan Chen; Utz Settmacher; Iver Petersen; Thomas Knösel
Journal:  J Clin Pathol       Date:  2011-07-01       Impact factor: 3.411

5.  Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer.

Authors:  G T Klus; N Rokaeus; M L Bittner; Y Chen; D M Korz; S Sukumar; A Schick; Z Szallasi
Journal:  Int J Oncol       Date:  2001-07       Impact factor: 5.650

6.  Cell adhesion and communication proteins are differentially expressed in melanoma progression model.

Authors:  Gisele Gargantini Rezze; José Humberto Tavares Guerreiro Fregnani; João Duprat; Gilles Landman
Journal:  Hum Pathol       Date:  2010-12-28       Impact factor: 3.466

7.  Loss of Desmocollin 3 in skin tumor development and progression.

Authors:  Jiangli Chen; Charlene O'Shea; James E Fitzpatrick; Maranke I Koster; Peter J Koch
Journal:  Mol Carcinog       Date:  2011-06-16       Impact factor: 4.784

8.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

Authors:  K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

9.  Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus.

Authors:  M C Boelens; A van den Berg; I Vogelzang; J Wesseling; D S Postma; W Timens; H J M Groen
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

10.  Expression of desmosomal proteins in squamous cell carcinomas of the skin.

Authors:  Hjalmar Kurzen; Ivonne Münzing; Wolfgang Hartschuh
Journal:  J Cutan Pathol       Date:  2003-11       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.